We will further explore the combination therapy strategies of SKLB-D18 with other anti-tumor drugs and its adaptability in different types of tumors, especially its potential in overcoming resistance to existing ERK1/2 and ERK5 inhibitors. This evidence concerns the gene MAPK7 and neoplasm.